Precision BioSciences, Inc. is the subject of a Schedule 13G reporting that investment manager Empery Asset Management, LP and Ryan M. Lane beneficially own 2,297,781 shares of its common stock, equal to 9.99% of the outstanding class. This total includes 103,146 shares issuable upon exercise of warrants, calculated using 22,897,665 shares of common stock outstanding as of November 10, 2025.
The filing explains that the warrants are subject to a 9.99% “Blocker,” which prevents the reporting persons from exercising warrants to the extent such exercise would push their beneficial ownership above 9.99%. Empery acts as investment manager to the funds that hold the shares and warrants, and Lane is described as an individual with indirect control over the investment manager. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Precision BioSciences, Inc.
(Name of Issuer)
Common Stock, $0.000005 par value per share
(Title of Class of Securities)
74019P207
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Empery Asset Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,297,781.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,297,781.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,297,781.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA, PN
Comment for Type of Reporting Person: Includes 103,146 shares of Common Stock issuable upon exercise of the Warrants (as defined in Item 2(a)).
SCHEDULE 13G
CUSIP No.
74019P207
1
Names of Reporting Persons
Ryan M. Lane
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,297,781.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,297,781.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,297,781.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 103,146 shares of Common Stock issuable upon exercise of the Warrants.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Precision BioSciences, Inc.
(b)
Address of issuer's principal executive offices:
302 East Pettigrew Street, Suite A-100, Durham, NC 27701
Item 2.
(a)
Name of person filing:
This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons," with respect to Common Stock, par value $0.000005 per share (the "Common Stock") and Common Stock issuable upon exercise of warrants (the "Warrants") of Precision BioSciences, Inc., a Delaware corporation (the "Company"):
(i) Empery Asset Management, LP (the "Investment Manager"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, funds to which the Investment Manager serves as investment manager (the "Empery Funds"); and
(ii) Mr. Ryan M. Lane ("Mr. Lane"), with respect to the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants held by, the Empery Funds.
The Investment Manager serves as the investment manager to each of the Empery Funds. Mr. Lane (the "Reporting Individual") is the managing member of a limited liability company that is the managing member of Empery AM GP, LLC (the "General Partner"), the general partner of the Investment Manager.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is:
1 Rockefeller Plaza, Suite 1205
New York, New York 10020
(c)
Citizenship:
Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
(d)
Title of class of securities:
Common Stock, $0.000005 par value per share
(e)
CUSIP No.:
74019P207
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 22,897,665 shares of Common Stock outstanding as of November 10, 2025, as reported in the Company's Prospectus Supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(5) on November 12, 2025, and assumes exercise of the Warrants (subject to the Blocker (as defined below)).
Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding shares of Common Stock (the "Blocker"), and the shares of Common Stock listed as beneficially owned in Rows 6, 8 and 9 of the cover page for each Reporting Person and the percentage set forth in Row 11 of the cover page for each Reporting Person give effect to the Blocker. Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Warrants due to the Blocker.
The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, the Empery Funds. The Reporting Individual, as the managing member of the limited liability company that is the managing member of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all of the Common Stock held by, and the Common Stock issuable upon exercise of the Warrants (subject to the Blocker) held by, the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individual hereby disclaims any beneficial ownership of any such Common Stock.
(b)
Percent of class:
9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a) above.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What ownership stake in Precision BioSciences (DTIL) does Empery report on this Schedule 13G?
The Schedule 13G reports that Empery Asset Management, LP and Ryan M. Lane beneficially own 2,297,781 shares of Precision BioSciences common stock, representing 9.99% of the outstanding class.
How is the 9.99% beneficial ownership in Precision BioSciences (DTIL) calculated?
The 9.99% figure is based on 22,897,665 shares of common stock outstanding as of November 10, 2025, as disclosed in a Precision BioSciences prospectus supplement, and includes shares issuable upon exercise of warrants subject to a blocker.
Do the Empery funds’ holdings in Precision BioSciences (DTIL) include warrants?
Yes. The reported beneficial ownership includes 103,146 shares of common stock issuable upon exercise of warrants, which are subject to a 9.99% ownership blocker limiting further exercise.
Who are the reporting persons on this Precision BioSciences (DTIL) Schedule 13G?
The reporting persons are Empery Asset Management, LP, which serves as investment manager to the Empery funds, and Ryan M. Lane, who is described as the managing member with indirect control over the investment manager’s general partner.
Are Empery and Ryan M. Lane seeking to influence control of Precision BioSciences (DTIL)?
The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Precision BioSciences, nor in connection with any transaction having that purpose or effect.
What voting and dispositive powers over Precision BioSciences (DTIL) shares are reported?
For each reporting person, the filing reports 0 shares with sole voting or dispositive power and 2,297,781 shares with shared voting and shared dispositive power, reflecting the structure of the Empery funds and their investment manager.
